Intermittent dosing of a rectal microbicide gel associated with sexual activity may be a more feasible strategy for long-term usage. Data are needed on the pharmacokinetics, safety, and acceptability of applying dapivirine gel as a lubricant in at-risk men who have sex with men (MSM) and transgender females who have sex with men.
MTN-033 was a Phase 1, randomized, open label, single-site trial designed to evaluate the pharmacokinetics of dapivirine gel (0.05%) when administered rectally via HTI vaginal applicator and a coital simulation device to healthy, HIV-1 uninfected men and transgender women. MTN-033 enrolled 16 participants ages 18 and older. Participants administered a single dose of dapivirine gel (DPV 0.05%) in each study sequence. They were randomized to one of two product application sequences. Product sequences included the application of a single dose of study product via applicator (2.5 g) and administration of up to 10 g of dapivirine gel applied via a coital simulation device (to simulate receptive anal intercourse); order of administration was randomly selected. A washout period occurred between each product application visit. This design allowed for the collection of valuable pharmacokinetic (PK) data from those exposed to a single dose of dapivirine gel rectally (which may be representative of episodic or coital dosing) with and without the use of a coital simulation device. The ideal coital-dosing regimens for dapivirine gel applied rectally are not yet known.
The study completed follow-up on December 5, 2018. Primary results were presented at the HIV Research for Prevention (HIVR4P) conference held virtually on January 27-28 and February 3-4, 2021. The primary manuscript is currently in development.
US Eunice Kennedy Shriver National Institute of Child Health and Human Development
US National Institute of Mental Health
US National Institutes of Health
Phase I, randomized, open label trial